Drug repositioning in SLE: Crowd-sourcing, literature-mining and Big Data analysis

Lupus

Volumn 25, Issue 10, 2016, Pages 1150-1170

  Grammer, A C ^a   Ryals, M M ^a   Heuer, S E ^a   Robl, R D ^a   Madamanchi, S ^a   Davis, L S ^b   Lauwerys, B ^c   Catalina, M D ^a   Lipsky, P E ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

drug repositioning; drug repurposing; HSCT; IL12; IL17; IL21; IL23; JAK; krill oil; LRxL STAT; LuCIN; MEDI 7169; meditation; mindfulness; quinacrine; ruxolitinib; secukinumab; Stelara; stem cells; tofacitinib; ustekinumab

Indexed keywords

ABACAVIR; ABATACEPT; ADALIMUMAB; APREMILAST; AZATHIOPRINE; BELIMUMAB; BORTEZOMIB; CARFILZOMIB; CERTOLIZUMAB PEGOL; CRIZOTINIB; DASATINIB; DIPYRIDAMOLE; ECULIZUMAB; ERLOTINIB; ETANERCEPT; EVEROLIMUS; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GEFITINIB; GLATIRAMER; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; NATALIZUMAB; OFATUMUMAB; PEMBROLIZUMAB; RITUXIMAB; TOCILIZUMAB; UNINDEXED DRUG; USTEKINUMAB;

ARTICLE; B LYMPHOCYTE; BIOINFORMATICS; CROWDSOURCING; DRUG EFFICACY; DRUG REPOSITIONING; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTOMICS; ANIMAL; BIOLOGY; DATA MINING; GENETICS; GENOMICS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROCEDURES;

ANIMALS; COMPUTATIONAL BIOLOGY; CROWDSOURCING; DATA MINING; DRUG REPOSITIONING; GENOMICS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84982924154     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316657437     Document Type: Article

References (55)

1. Lan Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens MH,. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today 2015; 20: 1027-1034.
2. Ashburn TT, Thor KB,. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004; 3: 673-683.
3. Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine. Drug repurposing and repositioning: workshop summary, Washington, DC: National Academies Press, 2014.
4. Minie M, Chopra G, Sethi G, et al. CANDO and the infinite drug discovery frontier. Drug Discov Today 2014; 19: 1353-1363.
5. Bisgin H, Liu Z, Kelly R, Fang H, Xu X, Tong W,. Investigating drug repositioning opportunities in FDA drug labels through topic modeling. BMC Bioinformatics 2012; 13 (Suppl 15): S6.
6. Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P,. Computational drug repositioning: from data to therapeutics. Clin Pharmacol Ther 2013; 93: 335-341.
7. Relle M, Weinmann-Menke J, Scorletti E, Cavagna L, Schwarting A,. Genetics and novel aspects of therapies in systemic lupus erythematosus. Autoimmun Rev 2015; 14: 1005-1018.
8. Deng Y, Tsao BP,. Advances in lupus genetics and epigenetics. Curr Opin Rheumatol 2014; 26: 482-492.
9. Marion TN, Postlethwaite AE,. Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus. Semin Immunopathol 2014; 36: 495-517.
10. Kyogoku C, Smiljanovic B, Grün JR, et al. Cell-specific type I IFN signatures in autoimmunity and viral infection: what makes the difference? PLoS One 2013; 8: e83776.
11. Smiljanovic B, Grün JR, Biesen R, et al. The multifaceted balance of TNF-α and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. J Mol Med 2012; 90: 1295-1309.
12. Kennedy WP, Maciuca R, Wolslegel K, et al. Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Lupus Sci Med 2015; 2: e000080.
13. Lauwerys BR, Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid. Arthritis Rheum 2013; 65: 447-456.
14. Chiche L, Jourde-Chiche N, Whalen E, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol 2014; 66: 1583-1595.
15. Jabbari A, Suárez-Fariñas M, Fuentes-Duculan J, et al. Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis. J Invest Dermatol 2014; 134: 87-95.
16. Berthier CC, Bethunaickan R, Gonzalez-Rivera T, et al. Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol 2012; 189: 988-1001.
17. Nzeusseu Toukap A, Galant C, Theate I, et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1579-1588.
18. Rai G, Rai R, Saeidian AH, Rai M,. Microarray to deep sequencing: transcriptome and miRNA profiling to elucidate molecular pathways in systemic lupus erythematosus. Immunol Res 2016; 64: 14-24.
19. Costa-Reis P, Russo PA, Zhang Z, et al. The role of microRNAs and human epidermal growth factor receptor 2 in proliferative lupus nephritis. Arthritis Rheumatol 2015; 67: 2415-2426.
20. Chung SA, Nititham J, Elboudwarej E, et al. Genome-wide assessment of differential DNA methylation associated with autoantibody production in systemic lupus erythematosus. PLoS One 2015; 10: e0129813.
21. Wu H, Zhao M, Tan L, Lu Q,. The key culprit in the pathogenesis of systemic lupus erythematosus: aberrant DNA methylation. Autoimmun Rev 2016; 15: 684-689.
22. Avorn J,. The $2.6 billion pill: methodologic and policy considerations. N Engl J Med 2015; 372: 1877-1879.
23. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Handout on Health: Systemic Lupus Erythematosus. Available at: http://www.niams.nih.gov/Health-Info/Lupus/default.asp (February 2015).
24. Aldridge C, Moddares M. Celebrating world lupus day: gaining ground with effective policy. Available at: http://www.huffingtonpost.com/chester-aldridge/celebrating-world-lupus-d-b-5302448.html (May 2014).
25. Grammer AC, Ryals M, Lipsky PE,. A comprehensive approach to identify approved drugs and treatments for repositioning as therapies for systemic lupus erythematosus. Arthritis Res Ther 2014; 16 (Suppl 1): A51.
26. Lipsky PE, Ryals M, Grammer AC,. A novel strategy to identify and evaluate approved drugs and treatments for repositioning as therapies for systemic lupus erythematosus (SLE). Arthritis Rheumatol 2014; 66: S294-S294.
27. Robl R, Catalina M, Heuer S, et al. Identification of novel pathway abnormalities in B cells from SLE patients. In: FOCIS 2015, San Diego, CA, 24-27 June 2015, paper no. W55. Federation of Clinical Immunology Societies.
28. Robl R, Heuer S, Catalina M, et al. Meta-analysis of SLE gene expression data identifies novel abnormalities in lymphocytes from the circulation, kidney, skin or synovium that define systemic networks of autoimmunity. Keystone Syst Immunol 2016, pp. 1029.
29. Grammer AC, Ryals MM, Catalina MD, Lipsky PE, Repositioning drugs for SLE. In: Tsokos G, Buyon J, Koike T, Lahita R, (eds). Systemic Lupus Erythematosus 2016 5th ed. 567-573.
30. Munos B. 2015 new drug approvals hit 66-year high. Available at: http://www.forbes.com/sites/bernardmunos/2016/01/04/2015-new-drug-approvals-hit-66-year-high/#6893f4441044 (January 2016).
31. Munos B. 2015 new drug approvals hit 66-year high. Available at: http://www.forbes.com/sites/bernardmunos/2016/01/04/2015-new-drug-approvals-hit-66-year-high/#6893f4441044 (January 2016).
32. Alliance for Lupus Research. New lupus clinical trial to study ustekinumab. Available at: http://www.lupusresearch.org/news-and-events/press-releases/alliance-for-lupus-research-7.html#.V4QmgTkrLgo (April 2015).
33. 2) are elevated in pre-clinical SLE and predict transition to classified disease prior to appearance of autoantibodies or clinical criteria. Arthritis Rheumatol 2014; 66: S708-S709.
34. Ichinose K, Arima K, Ushigusa T, et al. Distinguishing the cerebrospinal fluid cytokine profile in neuropsychiatric systemic lupus erythematosus from other autoimmune neurological diseases. Clin Immunol 2015; 157: 114-120.
35. Watanabe H, Mamelak AJ, Weiss E, et al. Anti-vascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model. Clin Cancer Res 2005; 11: 407-409.
36. Vazgiourakis VM, Zervou MI, Eliopoulos E, et al. Implication of VEGFR2 in systemic lupus erythematosus: a combined genetic and structural biological approach. Clin Exp Rheumatol 2013; 31: 97-102.
37. Li H, Pauza CD,. CD25(+) Bcl6(low) T follicular helper cells provide help to maturing B cells in germinal centers of human tonsil. Eur J Immunol 2015; 45: 298-308.
38. Ding Y, Li J, Yang P, et al. Interleukin-21 promotes germinal center reaction by skewing the follicular regulatory T cell to follicular helper T cell balance in autoimmune BXD2 mice. Arthritis Rheumatol 2014; 66: 2601-2612.
39. Feng X, Wang D, Chen J, et al. Inhibition of aberrant circulating Tfh cell proportions by corticosteroids in patients with systemic lupus erythematosus. PLoS One 2012; 7: e51982.
40. Lugar PL, Love C, Grammer AC, Dave SS, Lipsky PE,. Molecular characterization of circulating plasma cells in patients with active systemic lupus erythematosus. PLoS One 2012; 7: e44362.
41. Campain A, Yang YH,. Comparison study of microarray meta-analysis methods. BMC Bioinformatics 2010; 11: 408.
42. Ramasamy A, Mondry A, Holmes CC, Altman DG,. Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Med 2008; 5: e184.
43. Brainarray chip definition files (CDFs). Open source. Available at: http://brainarray.mbni.med.umich.edu/Brainarray/Database/customcdf/genomic-curated-CDF.asp (2016).
44. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43: e47.
45. Langfelder P, Horvath S,. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008; 9: 559.
46. De Souza A, Ali-Shaw T, Strober BE, Franks AG Jr,. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol 2011; 147: 896-898.
47. Gharibi T, Majidi J, Kazemi T, Dehghanzadeh R, Motallebnezhad M, Babaloo Z,. Biological effects of IL-21 on different immune cells and its role in autoimmune diseases. Immunobiology 2016; 221: 357-367.
48. I. Santos. Kadmon Corporation's lupus treatment candidate KD025 designated top priority. Available at: http://lupusnewstoday.com/2015/01/09/kadmon-corporations-lupus-treatment-candidate-designated-top-priority/ (January 2016).
49. Vugmeyster Y, Guay H, Szklut P, et al. In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus. MAbs 2010; 2: 335-346.
50. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K,. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007; 178: 3822-3830.
51. Yang X, Yang J, Chu Y, et al. T follicular helper cells mediate expansion of regulatory B cells via IL-21 in Lupus-prone MRL/lpr mice. PLoS One 2013; 8: e62855.
52. Rankin AL, Guay H, Herber D, et al. IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice. J Immunol 2012; 188: 1656-1667.
53. Hsu HC, Yang P, Wang J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008; 9: 166-175.
54. Amarilyo G, Lourenço EV, Shi FD, La Cava A,. IL-17 promotes murine lupus. J Immunol 2014; 193: 540-543.
55. Wen Z, Xu L, Xu W, et al. Interleukin-17 expression positively correlates with disease severity of lupus nephritis by increasing anti-double-stranded DNA antibody production in a lupus model induced by activated lymphocyte derived DNA. PLoS One 2013; 8: e58161.